Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apricoxib SCHEMBL346028 | 0.88 | CA1 (0.60) | PTGS2PTGS1CA1CA2CA12 | |
| Apricoxib SCHEMBL3435344 | 0.88 | CA1 (0.60) | PTGS2PTGS1CA1CA2CA12 | |
| SCHEMBL5308912 | 0.81 | PTGS2 (0.64) | PTGS2PTGS1CA1CA2CA12 | |
| SCHEMBL17920087 | 0.81 | PTGS2 (0.64) | PTGS2PTGS1CA1CA2CA12 | |
| SCHEMBL5314130 | 0.79 | CA9 (0.62) | PTGS2PTGS1CA1CA2CA12 | |
| SCHEMBL2464617 | 0.77 | PTGS2 (0.59) | PTGS2PTGS1CA1CA2CA12 | |
| SCHEMBL22330601 | 0.76 | CHRNA7 (0.64) | PTGS2PTGS1CA1CA2CA12 | |
| SCHEMBL4706398 | 0.76 | CA2 (1.00) | PTGS2PTGS1CA1CA2CA12 | |
| SCHEMBL21675750 | 0.75 | PTGS2 (0.62) | PTGS2PTGS1CA1CA2CA12 | |
| SCHEMBL21675742 | 0.75 | CHRNA7 (0.58) | PTGS2PTGS1CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2175722-A2 | PATIENT SELECTION AND THERAPEUTIC METHODS USING MARKERS OF PROSTAGLANDIN METABOLISM | Tragara Pharmaceuticals, Inc. (US) | 2010-04-21 | — | — | EP | claimed |
| WO-2009009776-A2 | PATIENT SELECTION AND THERAPEUTIC METHODS USING MARKERS OF PROSTAGLANDIN METABOLISM | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | WO | claimed |
| EP-2224932-A1 | CANCER TREATMENT USING COX-2 INHIBITOR AND ANTIMETABOLITE COMBINATIONS | Tragara Pharmaceuticals, Inc. (US) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009070547-A1 | CANCER TREATMENT USING COX-2 INHIBITOR AND ANTIMETABOLITE COMBINATIONS | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | WO | disclosed |